Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.
ONCOLOGY® Companion, Volume 39, Supplement 7
Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.
Advertisement
Advertisement
Trending on CancerNetwork
1
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
2
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
3
Examining Developments in Safe Administration of Nuclear Agents
4
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
5
